Onyx Biotec Q2 FY27 Share Price & Earnings Call Analysis

₹39.55+4.91% today
Market cap
₹72 Cr
ROE
-0.38%
Price to sales
1.03
Debt to equity
0.27
52W high / low
₹48.4 / ₹28.6
EBITDA margin
4.91%
Net profit margin
-0.30%
Promoter holding
41.74%
Sales (last year)
₹69 Cr

Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas, through a B2B business model[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. 1
  3. 3

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Onyx Biotec shareholding (Sep 2026)

Promoters

41.74%

−23.36 pp QoQ

FIIs

0.22%

−0.85 pp QoQ

DIIs

2.39%

unchanged QoQ

Public

55.64%

+24.20 pp QoQ

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹3,142 Cr34.2
240%+Up 2%+₹489 Cr16.7
340%+Up 0–2%₹234 Cr17.8
440%+Flat₹18,464 Cr1614.0
540%+Flat₹9,050 Cr34.8
640%+Flat₹4,493 Cr—

Financials of Onyx Biotec

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Onyx Biotec

Shareholding breakup across reporting periods.

Nov 2024Mar 2025Sep 2025Mar 2026Sep 2026
Promoters +65.10%65.10%65.10%65.10%41.74%
FIIs +8.72%5.36%1.95%1.07%0.22%
DIIs +3.29%2.39%2.39%2.39%2.39%
Public +22.89%27.15%30.56%31.44%55.64%
No. of Shareholders1,181551640586631

Pros & Cons

Onyx Biotec

Key positives and risks surfaced from the company insights section.

Pros
  • Promoter holding has decreased over last quarter: -23.4%
  • Company has a low return on equity of 6.12% over last 3 years.
Raw Insights
  • Promoter holding has decreased over last quarter: -23.4%
  • Company has a low return on equity of 6.12% over last 3 years.

Financials of Onyx Biotec

Quarterly Results

Quarter-by-quarter operating performance

No quarterly results data available for this company yet.

Financials of Onyx Biotec

Profit & Loss

Annual income statement trend

Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +44.8639.4953.7561.9569.4778.29
Sales growth-11.97%+36.11%+15.26%+12.14%+17.92%
Expenses +39.0934.9945.3651.5766.0672.98
Operating Profit5.774.508.3910.383.415.31
OPM %12.86%11.40%15.61%16.76%4.91%6.78%
Other Income +0.120.110.131.170.440.60
Interest0.650.572.162.021.221.21
Depreciation1.451.491.873.053.052.94
Profit before tax3.792.554.496.48-0.421.76
Tax %11.61%27.45%19.15%23.46%-50.00%
Net Profit +3.351.843.634.95-0.211.63
EPS in Rs2.511.382.722.73-0.120.90
Dividend Payout %0.00%0.00%0.00%0.00%0.00%

Financials of Onyx Biotec

Balance Sheet

Capital structure and asset base

Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital5.905.9013.3218.1318.1318.13
Reserves10.4712.3011.9737.4937.2838.22
Borrowings +12.2529.2330.7812.4615.1710.81
Other Liabilities +8.2211.3018.0723.1724.5826.23
Total Liabilities36.8458.7374.1491.2595.1693.39
Fixed Assets +17.2342.5043.4840.9039.1636.80
CWIP4.020.000.000.003.686.23
Investments0.000.000.000.000.000.00
Other Assets +15.5916.2330.6650.3552.3250.36
Total Assets36.8458.7374.1491.2595.1693.39

Financials of Onyx Biotec

Cash Flows

Operating, investing and financing cash movement

Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +0.491.961.521.42-1.49
Cash from Investing Activity +-5.78-22.68-3.150.66-4.58
Cash from Financing Activity +5.2016.433.095.071.50
Net Cash Flow-0.09-4.301.467.15-4.57
Free Cash Flow-5.30-20.78-1.701.91-6.48
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit8%44%18%14%-44%

Financials of Onyx Biotec

Ratios

Working capital efficiency and return ratios

Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days68.5146.95104.37119.19144.49
Inventory Days41.98109.9292.94150.1499.20
Days Payable59.46120.16140.83156.02124.70
Cash Conversion Cycle51.0336.7156.48113.32118.98
Working Capital Days35.72-52.2237.6287.4977.29
ROCE %8.23%12.85%12.16%1.15%

Onyx Biotec: frequently asked questions

What is Onyx Biotec share price today?

Onyx Biotec last traded at ₹39.55, with a market capitalisation of ₹72 Cr.

What is the promoter holding in Onyx Biotec?

Promoters held 41.74% of Onyx Biotec in Sep 2026 (−23.36 pp versus Mar 2026).

How much do FIIs and DIIs hold in Onyx Biotec?

In Sep 2026, foreign institutional investors held 0.22% and domestic institutions (including mutual funds) held 2.39% of Onyx Biotec.

What is Onyx Biotec's ROE and ROCE?

Onyx Biotec's return on equity is -0.38% and its return on capital employed is 1.15%.

Does Onyx Biotec pay a dividend?

Onyx Biotec's dividend yield is 0% at the current price; see the Onyx Biotec dividends page for past payouts.

Which sector does Onyx Biotec belong to?

Onyx Biotec is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.

What did Onyx Biotec's management say on the latest earnings call?

Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Onyx Biotec's management.

How does Arthneeti AI analyse Onyx Biotec?

Arthneeti reads Onyx Biotec's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.

What Onyx Biotec's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem